Skip to main content
CRDL logo

Cardiol Therapeutics Inc.

CRDLNASDAQHealthcareDrug Manufacturers - Specialty & Generic

$1.14Today:- (-)1Y −1.71%

As of Oct 27, 2026 close

Market cap
$131.03M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.88$2.34
Volume (live)
-
Avg. volume (3M)
1.31M

Cardiol Therapeutics (CRDL) Income Statement

In fiscal 2025 (fiscal year ended Mar 31, 2026), Cardiol Therapeutics posted a net loss of CAD 33.82M, compared with a net loss of CAD 36.68M a year earlier.

Cardiol Therapeutics Income Statement Analysis

Values in millions CAD

Income StatementBalance SheetCash FlowRatios
Scroll to see more
Cardiol Therapeutics Inc. income statement - Annual data in millions CAD
BreakdownFY 2025FY 2025FY 2024FY 2024FY 2023FY 2023FY 2022FY 2021FY 2020FY 2020FY 2019FY 2018FY 2017
Period endingMar 2026Dec 2025Mar 2025Dec 2024Mar 2024Dec 2023Dec 2022Dec 2021Mar 2021Dec 2020Dec 2019Dec 2018Dec 2017
Revenue & Gross Profit
Revenue0.00-0.00-0.00-0.000.080.00-0.000.000.00
Cost of Revenue0.00-0.37-0.25-0.220.220.23-0.150.090.05
Gross Profit0.00--0.37--0.25--0.220.08-0.23--0.15-0.09-0.05
Operating Expenses
Research & Development14.0214.0214.0114.0114.2214.2218.9610.8710.5210.603.531.530.44
Selling, General & Administrative20.2020.2025.8926.2615.5615.5622.3727.879.9510.0910.455.871.10
Operating Expenses34.3234.3239.9040.2829.5429.7941.3438.7420.6920.6914.137.491.60
Operating Income-34.32-34.32-40.28-40.28-29.79-29.79-41.34-38.66-20.61-20.69-13.58-7.49-1.60
Other Income/Expense
Interest Income0.730.731.191.192.042.041.240.110.080.080.250.100.01
Interest Expense0.00-0.00-0.00-0.000.000.00-0.000.660.06
Other Income/Expense0.50-0.233.603.601.661.6610.417.030.050.010.44-8.40-0.07
Income
Income Before Tax-33.82-33.82-36.68-36.68-28.13-28.13-30.93-31.64-20.64-20.64-13.68-15.89-1.66
Income Tax Expense0.00-0.00-0.00--19.41-6.910.01-0.300.000.00
Net Income-33.82-33.82-36.68-36.68-28.13-28.13-30.93-31.64-20.65-20.64-13.98-15.89-1.66
Net Income - Continuous Operations-33.82-33.82-36.68-36.68-28.13-28.13-11.52-24.72-20.65--13.98-15.89-1.66
Net Income - Discontinued Operations-------------
EBITDA-34.21-34.21-36.30-39.97-27.88-29.59-41.16-38.44-20.41-20.46-13.53-15.14-1.55
EBIT--34.32--40.28--29.79-41.34-38.66--20.69---
Depreciation & Amortization0.100.100.370.160.250.200.180.220.230.230.150.090.05
Earnings Per Share
Basic EPS---1.00-1.00----1.00-1.00-1.00-1.00-1.00-
Diluted EPS---1.00-1.00----1.00-1.00-1.00-1.00-1.00-
Basic Shares Outstanding86.9986.9971.5771.5764.4664.4662.5143.2229.8629.8625.8215.3722.71
Diluted Shares Outstanding86.9986.9971.5771.5764.4664.4662.5143.2229.8629.8625.8215.3722.71

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Cardiol Therapeutics Financial Statements

Is Cardiol Therapeutics profitable?

No. Cardiol Therapeutics reported a net loss of CAD 33.82M in fiscal 2025. In fiscal 2024 it lost CAD 36.68M.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition